Cancer Research UK aims for £230 million funding in 2004-05:
This article was originally published in Clinica
Executive Summary
Cancer Research UK (CRUK) invested £213m ($392m) in 2003-04 forresearch into cancer and is currently aiming to increase its annual spend by 7.5% - around £229m. So says the UK's leading charity for the promotion of research into the prevention, detection and treatment of cancer in its annual report. So far this year, it is already £20m ahead, says CRUK. Last year's successes include investigating the potential of flexible sigmoidoscopy as a screening tool for bowel cancer, for preventing up to 5,000 cases a year and work to discover the genes that could explain non-hereditary forms of ovarian and breast cancer. It also highlighted its strong support for the National Cancer Research Network, helping to treble the number of patients involved in clinical trials in the UK.
You may also be interested in...
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.
Mustang Bio Enters Race For CAR-T In Autoimmune Disease
The biotech company’s CEO talked to Scrip about plans to bring the CD20-targeting CAR-T MB-106 into an investigator-sponsored Phase I trial later this year.
Aldeyra Hopes To Refile Dry Eye Drug Reproxalap Later In 2024
Following an FDA complete response letter last November, Aldeyra has agreed with the agency on a trial design to demonstrate efficacy in ocular discomfort, which the company can complete this year.